Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer: Standardization of specimen processing;Molekularpathologische Diagnostik in der Zytopathologie des nichtkleinzelligen Lungenkarzinoms: Standardisierung der Materialprozessierung

Pathologe

Volumn 34, Issue 4, 2013, Pages 310-317

  Warth, A ^a,i   Bubendorf, L ^b,i   Gutz S ^c   Morresi Hauf, A ^d,i   Hummel, M ^e   Junker, K ^f,i   Lehmann, U ^g   Petersen, I ^h,i   Schnabel, P A ^a,i  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Robert Koch Klinik   (Germany)

^d Institut für Pathologie   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f KLINIKUM BREMEN MITTE   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

ⁱ Arbeitsgemeinschaft Pneumopathologie der Deutschen Gesellschaft für Pathologie ^*  (Germany)

Author keywords

Cytology; EGFR; Lung cancer; Pathology, molecular; Personalized medicine

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TUMOR MARKER;

BIOPSY; COOPERATION; GENE TRANSLOCATION; GENETICS; HUMAN; INTERDISCIPLINARY COMMUNICATION; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MOLECULAR PATHOLOGY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROGNOSIS; REVIEW; STANDARD;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; HUMANS; INDIVIDUALIZED MEDICINE; INTERDISCIPLINARY COMMUNICATION; LUNG; LUNG NEOPLASMS; MUTATION; PATHOLOGY, MOLECULAR; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84880921581     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-013-1764-3     Document Type: Review

References (35)

1. Bruno P, Mariotta S, Ricci A et al (2011) Reliability of direct sequencing of EGFR: comparison between cytological and histological samples from the same patient. Anticancer Res 31:4207-4210
2. Bubendorf L, Feicher G, Obermann P et al (2011) Zytopathologie, Pathologie, Bd 9. Springer, Berlin
3. Chowdhuri SR, Xi L, Pham TH et al (2012) EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol 25:548-555
4. Do H, Dobrovic A (2009) Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Mol Cancer 8:82
5. Fassina A, Gazziero A, Zardo D et al (2009) Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 62:1096-1102
6. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA: Cancer J Clin 61:69-90
7. Kellermann L, Ukena D (2012) Disparities In Access To EGFR-Mutation Testing In Patients With Advanced NSCLC In Germany 2011. Poster Session II, ISPOR 15th Annual European Congress, 3-7 November, Berlin, Germany
8. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703
9. Little AG, Gay EG, Gaspar LE et al (2007) National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 57:253-260
10. Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865
11. Mok TS (2011) Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 8:661-668
12. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
13. Molina-Vila MA, Bertran-Alamillo J, Reguart N et al (2008) A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol 3:1224-1235
14. Morinaga R, Okamoto I, Fujita Y et al (2008) Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. Cancer Sci 99:2455-2460
15. Pao W, Ladanyi M (2007) Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13:4954-4955
16. Penzel R, Schirmacher P, Warth A (2012) A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. J Thorac Oncol 7:1198-1199
17. Penzel R, Sers C, Chen Y et al (2011) EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch 458:95-98
18. Petersen I, Schnabel PA (2011) What's new in lung pathology: minutes from the Pulmonary Pathology Working Group of the German Society of Pathology. Pathologe 32(Suppl 2):351-357
19. Pirker R, Herth FJ, Kerr KM et al (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5:1706-1713
20. Rekhtman N, Brandt SM, Sigel CS et al (2011) Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 6:451-458
21. Riaz SP, Luchtenborg M, Jack RH et al (2012) Variation in surgical resection for lung cancer in relation to survival: population-based study in England 2004-2006. Eur J Cancer 48:54-60
22. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246
23. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467
24. Savic S, Bihl MP, Bubendorf L (2012) Non-small cell lung cancer: subtyping and predictive molecular marker investigations in cytology. Pathologe 33:301-307
25. Savic S, Tapia C, Grilli B et al (2008) Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. Br J Cancer 98:154-160
26. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566
27. Solomon SB, Zakowski MF, Pao W et al (2010) Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 194:266-269
28. Tapia C, Savic S, Bihl M et al (2009) EGFR mutation analysis in non-small-cell lung cancer: experience from routine diagnostics. Pathologe 30:384-392
29. Thunnissen E, Kerr KM, Herth FJ et al (2012) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 76:1-18
30. Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285
31. Warth A, Muley T, Herpel E et al (2012) Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 61:1017-1025
32. Warth A, Muley T, Meister M et al (2012) The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438-1446
33. Warth A, Penzel R, Brandt R et al (2012) Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch 460:407-414
34. Weihmann J, Weichert C, Petersen I et al (2012) Evaluation of a cell block method in cytological diagnostics. Pathologe 33:553-559
35. Zlobec I, Raineri I, Schneider S et al (2010) Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. Lung Cancer 68:192-197